Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.800 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	449
Open	1.800
Bid (Size)	1.800 (400)
Ask (Size)	1.820 (200)
Prev. Close	1.800
Today's Range	1.800 - 1.800
52wk Range	0.8800 - 1.820
Shares Outstanding	65,352,279
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial ↗

August 12, 2026

Cardiol Therapeutics (NASDAQ:CRDL) is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management...

Via MarketBeat

Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

April 29, 2026

Via Get News

Performance

YTD	+81.1%	+81.1%
1 Month	+48.8%	+48.8%
3 Month	+40.6%	+40.6%
6 Month	+73.1%	+73.1%
1 Year	+47.5%	+47.5%

More News

Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)

April 27, 2026

Via Get News

$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

April 13, 2026

Via Get News

On Tuesday, there are stocks with unusual volume. Let's take a look. ↗

March 31, 2026

Via Chartmill

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

Via PressReach

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 01, 2025

Via Newsfile

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

August 06, 2025

Via PressReach

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗

June 02, 2025

Via Benzinga

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

April 16, 2025

Via Newsfile

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options

March 27, 2025

Via Investor Brand Network

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart

February 20, 2025

Via Newsfile

“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”

December 06, 2024

Via AB Newswire

3 Penny Stocks Ready to Break Out in 2025

November 29, 2024

Via MarketBeat

Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!

November 25, 2024

Via AB Newswire

“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”

November 21, 2024

Via AB Newswire

Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…

November 21, 2024

Via AB Newswire

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study ↗

November 19, 2024

Via Benzinga

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

November 18, 2024

Via AB Newswire

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024

Via Newsfile

“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”

November 13, 2024

Via AB Newswire

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

November 07, 2024

Via AB Newswire

“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”

November 05, 2024

Via AB Newswire

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”

October 28, 2024

Via AB Newswire

Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX

October 23, 2024

Via AB Newswire

Frequently Asked Questions

Is Cardiol Therapeutics Inc. - Class A Common Shares publicly traded?

Yes, Cardiol Therapeutics Inc. - Class A Common Shares is publicly traded.

What exchange does Cardiol Therapeutics Inc. - Class A Common Shares trade on?

Cardiol Therapeutics Inc. - Class A Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares?

The ticker symbol for Cardiol Therapeutics Inc. - Class A Common Shares is CRDL on the Nasdaq Stock Market

What is the current price of Cardiol Therapeutics Inc. - Class A Common Shares?

The current price of Cardiol Therapeutics Inc. - Class A Common Shares is 1.800

When was Cardiol Therapeutics Inc. - Class A Common Shares last traded?

The last trade of Cardiol Therapeutics Inc. - Class A Common Shares was at 08/14/26 04:00 PM ET

What is the market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares?

The market capitalization of Cardiol Therapeutics Inc. - Class A Common Shares is 117.63M

How many shares of Cardiol Therapeutics Inc. - Class A Common Shares are outstanding?

Cardiol Therapeutics Inc. - Class A Common Shares has 118M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.